Table 1. Incidence of tumor formation after transplanting HeLa cells in various immunodeficient mice.
| strain | use of Matrigel | min.dose fortumor formation | weeks to observeTumor (first to last) | number of mice | Log10TPD50 |
| nude | with | 1×104 cells | 3 to 8 | 120 | 3.5 |
| nude | w/o | 1×104 cells | 4 to 12 | 120 | 4.9 |
| SCID | with | 1×103 cells | 3 to 11 | 24 | 2.5 |
| SCID | w/o | 1×103 cells | 3 to 11 | 24 | 3.83 |
| NOD-SCID | with | 1×102 cells | 3 to 16 | 24 | 2.17 |
| NOD-SCID | w/o | 1×103 cells | 3 to 14 | 24 | 3.5 |
| NOG | with | 1×101 cells | 5 to 18 | 75 | 1.1 |
| NOG | w/o | 1×104 cells | 3 to 13 | 105 | 3.97 |
Log10TPD50 values for HeLa cells transplanted subcutaneously into various immunodeficient mouse strains with or without Matrigel. Tumor-forming potentials of HeLa cells in nude mice without Matrigel and in NOG mice with Matrigel are highlighted in gray.